School-based Treatment of Social Anxiety With Developmentally Oriented Cognitive Therapy for Social Anxiety Disorder
Launched by KLAUS RANTA · Jun 28, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of therapy called Developmentally Oriented Cognitive Therapy for Social Anxiety Disorder (DOCT-SAD) to see if it works better than standard counseling for teenagers aged 12 to 17 who have Social Anxiety Disorder. The goal is to help these young people manage their anxiety and improve their overall well-being. The trial will compare the effectiveness of DOCT-SAD, which is delivered by specially trained school psychologists, with standard counseling provided by school staff who are not specifically trained in this method.
To participate in the study, teenagers must be between 13 and 17 years old, have a diagnosis of Social Anxiety Disorder, and be motivated to attend the therapy sessions. They will receive treatment for 10 weeks and will have follow-up assessments at six and twelve months to see how well they are doing. It's important to note that certain conditions, like severe depression or other mental health issues that need immediate attention, may prevent someone from participating in this trial. Overall, this study aims to find out the best way to help young people cope with social anxiety and improve their quality of life.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • age 13-17 years
- • diagnosis of DSM-5 SAD (Social Anxiety Disorder)
- • SAD is the primary mental health disorder
- • motivation of the adolescent and parent to attend DOCT-SAD / SC as described in the study protocol
- • good command of the Finnish language.
- Exclusion criteria:
- • intellectual deficit
- • presence of primary autism spectrum disorder
- • marked psychotic symptoms or psyhotic disorder
- • severe eating disorder, depression or primary other anxiety disorder requiring acute treatment which need to be prioritized above treatment of social anxiety
- • acute suicidality or suicide risk
- • substance use or substance use disorder requiring child protection measures
- • presence of contextual/environmental risk factors in the participants surroundings which require child protection measures
About Klaus Ranta
Klaus Ranta is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative clinical studies. With a strong focus on ethical practices and regulatory compliance, Klaus Ranta collaborates with leading research institutions and healthcare professionals to design and implement rigorous clinical trials. The organization emphasizes transparency, patient safety, and scientific integrity, aiming to contribute valuable insights to the medical community and enhance therapeutic options for a range of health conditions. Through strategic partnerships and a patient-centered approach, Klaus Ranta strives to bring novel therapies from the lab to the clinic efficiently and effectively.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampere, Pirkanmaa, Finland
Patients applied
Trial Officials
Klaus Ranta, MD, PhD
Study Director
Tampere University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported